Research progress of application of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syn-drome / 心血管康复医学杂志

ABSTRACT

Through occupying binding site of glycoprotein IIb/IIIa receptor,platelet glycoprotein IIb/IIIa inhibitor (GPI)inhibit the combination of fibrinogen and the receptor,then inhibit platelet aggregation.GPI is the most powerful anti-platelet drug and possesses application value in ACS now.This article made an overview on the newest research progress of safety and effectiveness of GPI in ACS.